Loading...
APTO.F logo

Aptose Biosciences Inc.OTCPK:APTO.F Stock Report

Market Cap US$3.7m
Share Price
US$1.68
US$1.83
8.2% undervalued intrinsic discount
1Y1.8%
7D-2.3%
Portfolio Value
​
View

Aptose Biosciences Inc.

OTCPK:APTO.F Stock Report

Market Cap: US$3.7m

Aptose Biosciences (APTO.F) Stock Overview

A clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. More details

APTO.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Does not have a meaningful market cap ($5M)

Negative shareholders equity


APTO.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Aptose Biosciences Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aptose Biosciences
Historical stock prices
Current Share PriceCA$1.68
52 Week HighCA$1.89
52 Week LowCA$0.64
Beta0.29
1 Month Change0%
3 Month Change1.20%
1 Year Change1.82%
3 Year Change-99.25%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 01

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q2 earnings results on Monday, August 1st, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 6 upward revisions and 0 downward.
Seeking Alpha • Jul 19

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023. There is a sizable market opportunity for drugs to address patients with hematological cancers who've progressed on other therapies, but the odds and timelines are long. I believe fair value for Aptose is around $4 today, but upside is tied to future positive clinical developments and there's not much room for stumbles or setbacks. It wouldn't be fair to say that there's been no clinical progress at Aptose Biosciences (APTO) since my last update, but there certainly hasn't been enough to really sway investor sentiment, particularly in light of a more risk-averse biotech market. Aptose has two credible hematological oncology products in the pipeline, but there is a still lot of de-risking needed for both programs. I do believe that the market is still heavily discounting the odds of clinical success here, but given the history of oncology drug development, and Aptose's own shaky clinical progress, that's not exactly unfair. I can still see a path toward a substantially higher fair value, but the reality is that investors are likely going to need to wait a year or more for sentiment-moving data. '239 Is Worth Further Exploration From five complete responses and one partial response back at the December 2021 ASH update, Aptose has seen two more complete responses in its HM43239 (or '239) program in relapsed or refractory AML, bringing the total to seven complete responses and one partial response among a 80mg, 120mg, and 160mg dosing group that has treated at least 41 patients as off the last cut-off (early June, ahead of the EHA meeting). Thus far the drug has shown encouraging safety/tolerability, with only one dose-limiting toxicity reported so far (muscle weakness in a patient getting a 200mg dose). While the response rates aren't eye-popping at this point, it's worth remembering that these are not the healthiest patients, as they've already seen drug progression after prior treatments. Based on the early clinical results, management is moving forward with further dose exploration at 80mg, 120mg, and 160mg (the 80mg segment has been completed, with the 120mg and 160mg cohorts about half-complete as of early June) and then two expansion studies. One expansion study will use 120mg (with 80mg and 160mg as bracketing dosages) of '293 as a single-agent therapy in FLT-3 mutated and unmutated AML, while the other will be a combination study with venetoclax (Venclexta, marketed by AbbVie (ABBV) and Roche (RHHBY)). The single-agent study should start later this year, with the combo study slated for the first half of 2023. Should the results of these studies merit it, registrational studies would then start - presumably in 2024 for the single-agent study. It's worth remembering that '293 is targeting the challenging r/r AML market. While there are solid treatment options available as front-line therapies, some patients cannot tolerate them, some do not respond, and others ultimately see their disease mutate around the treatment and become non-responsive/relapsing. Keep this in mind when comparing response rates to other drugs in the space (make sure it's an "apples to apples" comparison). Another Chance For Luxeptinib Aptose's prior lead drug, luxeptinib, still factors significantly into the company's clinical plans today. While the drug showed exciting pre-clinical attributes, clinical results today have not matched that potential. It would seem that the pharmacokinetics of the drug are at least partly to blame, and the company is hoping that a reformulated version of the drug (known as "G3") can lead to patients getting consistent therapeutic doses that produce clinical results. Clinical trial work is underway now, with patients getting G3 at 50mg, 100mg, and 200mg doses and the 50mg dose of G3 demonstrating 200x the exposure level of a 150mg dose of G1. Assuming that the pharmacokinetics and pharmacodynamics (PK and PD) studies merit further development, Aptose should be able to start dose escalation studies of the new formulation in the first half of 2023 in patients with r/r B-cell or r/r AML disease.
Seeking Alpha • Feb 02

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech. A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, but it's a "show me" story. Recently-acquired '239 looks like an interesting asset for AML, with promising Phase 1 response rates, but it's still early in the development cycle. Between '239 and luxeptinib there is still potential in Aptose's pipeline, but it will take real evidence of clinical efficacy to rebuild sentiment.

Shareholder Returns

APTO.FUS BiotechsUS Market
7D-2.3%1.2%2.1%
1Y1.8%41.9%30.6%

Return vs Industry: APTO.F underperformed the US Biotechs industry which returned 41.9% over the past year.

Return vs Market: APTO.F underperformed the US Market which returned 31% over the past year.

Price Volatility

Is APTO.F's price volatile compared to industry and market?
APTO.F volatility
APTO.F Average Weekly Movement4.3%
Biotechs Industry Average Movement10.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: APTO.F has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: APTO.F's weekly volatility has decreased from 14% to 4% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198614William Ricewww.aptose.com

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd.

Aptose Biosciences Inc. Fundamentals Summary

How do Aptose Biosciences's earnings and revenue compare to its market cap?
APTO.F fundamental statistics
Market capUS$3.74m
Earnings (TTM)-US$25.47m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.2x
P/E Ratio

Is APTO.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APTO.F income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$25.47m
Earnings-US$25.47m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-9.98
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-99.5%

How did APTO.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 09:23
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aptose Biosciences Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew VeneziaAlliance Global Partners
Dylan DupuisB. Riley Securities, Inc.
John NewmanCanaccord Genuity